Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes
- PMID: 23266293
- DOI: 10.1016/j.antiviral.2012.12.008
Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes
Abstract
Current treatment of chronic hepatitis B virus (HBV) infection mainly targets viral replication in hepatocytes and leads to curing only in exceptional cases. Despite their potential to improve therapeutic success, no drugs interfering with early infection steps of the hepatotropic pathogen HBV are available to date. Recently, entry of the hepatitis C virus (HCV) has been shown to occur along hepatic cholesterol uptake pathways and ezetimibe, a drug which blocks this lipid transport, has been shown to inhibit HCV infection. We here investigated the effect of ezetimibe on HBV infection using differentiated HepaRG cells as a cell-culture infection model. Treatment with ezetimibe inhibited establishment of intrahepatic cccDNA and expression of viral replication markers when cells were infected with HBV virions, while we observed no effect when the HBV viral genome was transduced via an adenoviral vector. Our data suggest that modulating hepatic cholesterol uptake by ezetimibe inhibits early HBV infection and that ezetimibe sensitive lipid transport pathways represent new targets for antiviral therapy in HBV infection.
Copyright © 2012. Published by Elsevier B.V.
Similar articles
-
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.J Hepatol. 2013 May;58(5):861-7. doi: 10.1016/j.jhep.2012.12.008. Epub 2012 Dec 13. J Hepatol. 2013. PMID: 23246506
-
(-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes.Antiviral Res. 2014 Nov;111:100-11. doi: 10.1016/j.antiviral.2014.09.009. Epub 2014 Sep 27. Antiviral Res. 2014. PMID: 25260897
-
Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an early step in the virus life cycle.Antiviral Res. 2018 Mar;151:4-7. doi: 10.1016/j.antiviral.2018.01.001. Epub 2018 Jan 5. Antiviral Res. 2018. PMID: 29309795
-
Inhibitors of hepatitis B virus attachment and entry.Intervirology. 2014;57(3-4):151-7. doi: 10.1159/000360948. Epub 2014 Jul 15. Intervirology. 2014. PMID: 25034482 Review.
-
Strategies to inhibit entry of HBV and HDV into hepatocytes.Gastroenterology. 2014 Jul;147(1):48-64. doi: 10.1053/j.gastro.2014.04.030. Epub 2014 Apr 25. Gastroenterology. 2014. PMID: 24768844 Review.
Cited by
-
Entry Inhibitors of Hepatitis B and D Viruses.Adv Exp Med Biol. 2022;1366:199-205. doi: 10.1007/978-981-16-8702-0_12. Adv Exp Med Biol. 2022. PMID: 35412142 Review.
-
Hepatitis B Virus Entry into Cells.Cells. 2020 Jun 18;9(6):1486. doi: 10.3390/cells9061486. Cells. 2020. PMID: 32570893 Free PMC article. Review.
-
Innovative HBV Animal Models Based on the Entry Receptor NTCP.Viruses. 2020 Jul 30;12(8):828. doi: 10.3390/v12080828. Viruses. 2020. PMID: 32751581 Free PMC article. Review.
-
Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets.Emerg Microbes Infect. 2018 Jul 26;7(1):134. doi: 10.1038/s41426-018-0137-7. Emerg Microbes Infect. 2018. PMID: 30050063 Free PMC article. Review.
-
Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide.Sci Rep. 2018 Feb 9;8(1):2769. doi: 10.1038/s41598-018-20987-w. Sci Rep. 2018. PMID: 29426822 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
